摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E) 6-(6-cyclopropyl-1,3-dihydro-4-hydroxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid

中文名称
——
中文别名
——
英文名称
(E) 6-(6-cyclopropyl-1,3-dihydro-4-hydroxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid
英文别名
(E) 6-(6-cyclopropyl-1,3-dihydro-4-hydroxy-7-methyl-3oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid;6-(6-cyclopropyl-1,3-dihydro-4-hydroxy-7-methyl-3oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid;(E)-6-(6-Cyclopropyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid;(E)-6-(6-cyclopropyl-4-hydroxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
(E) 6-(6-cyclopropyl-1,3-dihydro-4-hydroxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid化学式
CAS
——
化学式
C19H22O5
mdl
——
分子量
330.381
InChiKey
BUOJHELHTNGCOY-XCVCLJGOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    83.8
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY
    申请人:Cannizzaro Carina
    公开号:US20090227543A1
    公开(公告)日:2009-09-10
    The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    本发明涉及磷酸酯取代化合物,具有免疫调节活性,含有这种化合物的组合物,以及包括这种化合物的给药的治疗方法,还涉及用于制备这种化合物的有用过程和中间体。
  • ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS
    申请人:Cannizzaro Carina
    公开号:US20090247488A1
    公开(公告)日:2009-10-01
    The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    本发明涉及磷取代的抗炎化合物、含有这种化合物的组合物、包括给药这种化合物的治疗方法,以及用于制备这种化合物的有用过程和中间体。
  • ANTI-CANCER PHOSPHONATE ANALOGS
    申请人:Boojamra Constantine G.
    公开号:US20100022467A1
    公开(公告)日:2010-01-28
    The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    本发明涉及磷取代的抗癌化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法,还涉及用于制备这些化合物的过程和中间体。
  • ANTIVIRAL PHOSPHONATE ANALOGS
    申请人:Boojamra Constantine G.
    公开号:US20090275535A1
    公开(公告)日:2009-11-05
    The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    这项发明涉及具有抗病毒活性的磷取代化合物,包含这种化合物的组合物以及包括给予这种化合物的治疗方法,还包括用于制备这种化合物的过程和中间体。
  • [EN] METABOLISM-MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DU MÉTABOLISME ET UTILISATIONS ASSOCIÉES
    申请人:UNIV QUEENSLAND
    公开号:WO2006017896A1
    公开(公告)日:2006-02-23
    The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5' monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
    本发明旨在提供调节脂肪生成的方法和试剂。更具体地,本发明涉及能够调节次黄嘌呤-5'一磷酸脱氢酶(IMPDH)的水平或功能活性的分子,以及它们在调节脂肪细胞中脂质的积累和/或脂肪细胞前体分化为脂肪细胞方面的作用,从而用于治疗或预防与脂肪量相关的疾病,包括但不限于肥胖症、脂肪瘤、脂肪瘤病、恶病质或脂肪营养不良,或由于创伤或萎缩性条件导致的脂肪组织损失。
查看更多